

THE ROLE OF PHARMACOMETRICS IN REGULATORY SCIENCE

*pre-meeting workshop for the
World Conference on Pharmacometrics (WCoP)*

Sunday, August 21, 2016
08:00 – 15:15

**Brisbane Convention and
Exhibition Centre
Brisbane, Australia
Meeting Room P3**

*Please register using the
following [LINK](#).*



The FDA's Critical Path Initiative identified modeling and simulation as a priority area of active research opportunities in regulatory science. Regulatory science is now recognized as more than just developing new methods for evaluating therapeutic candidates in a more efficient manner. It requires a cultural shift relating to how drug developers, patients and regulators view the tradeoff between risk and reward. Collaboration among disciplines offers a particularly productive venue for developing a regulatory science workforce. The Coalition Against Major Diseases (CAMD) is convening a pre-meeting workshop in association with WCoP with the goals of discussing with the modeling and simulation community, the areas of cross-fertilization between pharmacometrics and regulatory science. The value proposition of quantitative drug-disease-trial models as drug development platforms will be highlighted, and case studies of the potential of novel and integrated data sources for the development of such models will be shared.

*The conference agenda is
available ([HERE](#)).*

Meeting Topics

- *Strategic ISoP/C-Path Alliance for the Advancement of Pharmacometrics and Regulatory Science*
- *Regulatory Science and Quantitative Drug Development Tools*
- *Digital Biomarkers and Quantitative Model*
- *Case Studies of Pharmacometrics Applied in Regulatory Science*



Klaus Romero, MD, MS, FCP
Director of Clinical Pharmacology
520.547.3440
kromero@c-path.org

Jennifer Ashley Ferstl, BA
Project Coordinator
520.382.1403
iferstl@c-path.org

